1. Home
  2. PGEN vs ZLAB Comparison

PGEN vs ZLAB Comparison

Compare PGEN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$7.70

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$26.43

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
ZLAB
Founded
1998
2013
Country
United States
China
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.6B
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
PGEN
ZLAB
Price
$7.70
$26.43
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$8.33
$49.60
AVG Volume (30 Days)
3.7M
767.1K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.46
EPS
0.03
N/A
Revenue
$230,981,000.00
$460,156,000.00
Revenue This Year
$1,115.92
$9.75
Revenue Next Year
$81.04
$26.03
P/E Ratio
$258.83
N/A
Revenue Growth
N/A
15.33
52 Week Low
$2.99
$15.96
52 Week High
$8.04
$34.72

Technical Indicators

Market Signals
Indicator
PGEN
ZLAB
Relative Strength Index (RSI) 64.70 60.70
Support Level $6.57 $16.84
Resistance Level $7.72 $27.22
Average True Range (ATR) 0.27 0.90
MACD 0.05 -0.13
Stochastic Oscillator 76.41 70.98

Price Performance

Historical Comparison
PGEN
ZLAB

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Share on Social Networks: